Department of Otolaryngology-Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Jingxi Street, Baiyun District, Guangzhou, 510515, People's Republic of China.
Department of Otolaryngology-Head and Neck Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.
J Cancer Res Clin Oncol. 2023 Jan;149(1):191-202. doi: 10.1007/s00432-022-04506-z. Epub 2023 Jan 3.
Systemic immune-inflammation index (SII) has been demonstrated to be closely associated with the poor prognosis of nasopharyngeal carcinoma (NPC). However, the role of SII during treatment of NPC has not been reported. This study aimed to determine the prognostic value of SII during treatment for NPC patients.
A total of 759 patients diagnosed with NPC were included in this retrospective study (393 in training cohort and 366 in validation cohort). The correlation between variables was analyzed by the chi-squared test, the Fisher's exact test or the likelihood test. Kaplan-Meier method and log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). The independent prognostic factors were determined by multivariate analysis of Cox proportional hazards regression model. The uncontrolled risk was analyzed by Logistic regression. Receiver operating characteristic (ROC) curves were used to assess prognostic value.
The optimal cut-off point for the SII during treatment was 937.32. High SII during treatment group had higher uncontrolled risk than low SII during treatment group (p = 0.008). In multivariate Cox proportional hazard models analysis, SII during treatment was an independent prognostic factor for 5-year PFS (p < 0.001) and 5-year OS (p < 0.001). All results were found in the training cohort and confirmed in the validation cohort.
The SII during treatment is a promising indicator of predicting the survival in NPC patients, especially the risk of uncontrolled occurrence. By monitoring the SII during treatment, it is possible to better evaluate the treatment effect and formulate personalized treatment.
系统免疫炎症指数（SII）已被证明与鼻咽癌（NPC）的不良预后密切相关。然而，SII 在 NPC 治疗中的作用尚未有报道。本研究旨在确定 SII 在 NPC 患者治疗期间的预后价值。
本回顾性研究纳入了 759 例确诊为 NPC 的患者（训练队列 393 例，验证队列 366 例）。采用卡方检验、Fisher 确切检验或似然比检验分析变量之间的相关性。采用 Kaplan-Meier 方法和对数秩检验分析无进展生存期（PFS）和总生存期（OS）。采用多因素 Cox 比例风险回归模型分析独立预后因素。采用 Logistic 回归分析不可控风险。采用受试者工作特征（ROC）曲线评估预后价值。
治疗期间 SII 的最佳截断点为 937.32。高治疗期间 SII 组的不可控风险高于低治疗期间 SII 组（p=0.008）。多因素 Cox 比例风险模型分析显示，治疗期间 SII 是 5 年 PFS（p<0.001）和 5 年 OS（p<0.001）的独立预后因素。所有结果均在训练队列中发现，并在验证队列中得到证实。
治疗期间的 SII 是预测 NPC 患者生存的有前途的指标，尤其是预测不可控发生的风险。通过监测治疗期间的 SII，可以更好地评估治疗效果并制定个性化治疗方案。
